Introduction: The Growing Challenge of ICI-Induced Cardiotoxicity
The landscape of oncology has been fundamentally transformed by the advent of immune checkpoint inhibitors (ICIs). By blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), these therapies have significantly improved survival across various malignancies. However, the non-specific activation of the immune system often leads to immune-related adverse events (irAEs). Among these, ICI-induced myocarditis is particularly feared. Although it occurs in less than 1% of patients, it carries a high mortality rate—often exceeding 40% to 50%—and frequently presents as a fulminant clinical course characterized by arrhythmias, heart failure, and cardiogenic shock.
The Emergence of LAG-3 Inhibition
The therapeutic horizon has recently expanded with the introduction of relatlimab, a monoclonal antibody targeting lymphocyte-activation gene 3 (LAG-3). When combined with nivolumab (anti-PD-1), relatlimab has shown superior efficacy in treating advanced melanoma. However, this potent combination has also been associated with a higher incidence of myocarditis compared to PD-1 monotherapy. Despite the clinical urgency, the specific immunological drivers that cause T cells to infiltrate the myocardium under dual LAG-3/PD-1 blockade have remained poorly understood until now.
Highlights of the Research
The study by Munir et al., published in Circulation, provides a comprehensive analysis of the mechanisms driving ICI myocarditis. The key highlights include:
Clinical Risk Validation
Utilizing VigiBase, the researchers confirmed that anti-LAG-3 combination therapies significantly increase the reporting odds ratio for myocarditis compared to other ICI regimens.
Identification of a Pathogenic T Cell Subset
The study identified CXCR6 (C-X-C motif chemokine receptor 6) as the definitive marker for the activated, clonally expanded T cells that infiltrate the heart.
The CXCL16-CXCR6 Axis
The ligand for CXCR6, known as CXCL16, was found to be upregulated in cardiac macrophages, creating a chemoattractant gradient that draws pathogenic T cells into the myocardial tissue.
A Novel Therapeutic Target
Pharmacological blockade of CXCR6 in preclinical models successfully prevented premature death, reduced the severity of arrhythmias, and attenuated histological signs of myocarditis.
Study Design and Methodology
The researchers employed a multi-faceted approach to bridge the gap between clinical observation and mechanistic understanding.
Pharmacovigilance Analysis
The team accessed VigiBase, the World Health Organization’s international database of individual safety reports. They specifically analyzed cases of myocarditis in patients receiving anti-LAG-3 therapy (primarily relatlimab) in combination with PD-1 inhibitors to assess the real-world risk relative to standard-of-care ICI treatments.
Preclinical Mouse Models
To simulate the dual checkpoint blockade, the researchers utilized a double-knockout mouse model (Lag3-/- and Pdcd1-/-). These mice genetically lack both LAG-3 and PD-1, providing a robust system to study the spontaneous development of myocarditis. The animals underwent rigorous phenotyping, including: histology to assess inflammatory infiltration; flow cytometry to characterize immune cell populations; and continuous electrocardiography (ECG) to monitor for arrhythmias.
Advanced Molecular Profiling
Single-cell RNA sequencing (scRNA-seq) was performed on cardiac-infiltrating immune cells. This allowed the researchers to map the transcriptomic landscape of the T cells and macrophages involved in the disease process. Finally, they conducted cellular depletion studies and used an anti-CXCR6 neutralizing antibody to test the necessity of these cells in driving the disease.
Key Findings: Unmasking the Driver of Cardiac Destruction
Severe Phenotype in Dual-Deficiency Models
The Lag3-/- Pdcd1-/- mice developed a severe, spontaneous myocarditis that mirrored the clinical presentation of human ICI myocarditis. By 6 to 8 weeks of age, these mice exhibited significant cardiac inflammation and experienced premature lethality. ECG monitoring revealed high-grade atrioventricular blocks and ventricular arrhythmias, which are the primary causes of death in human patients.
CXCR6 as the Hallmark of Pathogenicity
The scRNA-seq data revealed a distinct population of T cells in the inflamed hearts. These cells were characterized by the high expression of CXCR6. This receptor was not merely a bystander; it was expressed on various subsets of T cells, including those expressing Granzyme K (Gzmk) and Granzyme B (Gzmb), as well as actively proliferating CD4+ and CD8+ cells. Importantly, this CXCR6 signature was validated against other preclinical models of ICI myocarditis and human patient samples, confirming its relevance across species.
The Role of Cardiac Macrophages
The study highlighted a critical crosstalk between T cells and the innate immune system. Cardiac macrophages in the diseased hearts showed a significant upregulation of CXCL16. This suggests that the myocardium becomes a pro-inflammatory environment where macrophages “recruit” CXCR6+ T cells, leading to a self-amplifying cycle of tissue damage.
Therapeutic Rescue via CXCR6 Inhibition
Perhaps the most clinically significant finding was the effect of targeting the CXCR6 pathway. Treatment with an anti-CXCR6 antibody significantly improved survival in the mouse models. It reduced the histological severity of the inflammatory infiltrate and, crucially, decreased the incidence of lethal arrhythmias. This suggests that blocking the migration of these specific T cells—rather than broad immunosuppression—could be a viable strategy.
Expert Commentary: Towards Precision Cardio-Oncology
The identification of CXCR6+ T cells represents a major leap forward in the field of cardio-oncology. Historically, the management of ICI myocarditis has relied on high-dose corticosteroids and potent immunosuppressants like mycophenolate mofetil or anti-thymocyte globulin. While these treatments can dampen the immune response, they are non-specific and can potentially counteract the anti-tumor efficacy of the ICIs.
Mechanistic Specificity
Experts in the field note that CXCR6 is particularly interesting because its expression is highly enriched in tissue-infiltrating T cells rather than circulating naive T cells. By targeting the CXCR6-CXCL16 axis, it may be possible to specifically prevent T cells from entering the heart without compromising the systemic T cell response required to fight cancer.
Limitations and Future Directions
While the preclinical data is compelling, several questions remain. The study primarily focused on the LAG-3/PD-1 combination. Whether CXCR6 plays an equally dominant role in CTLA-4-induced myocarditis requires further validation. Furthermore, moving from a mouse anti-CXCR6 antibody to a humanized version for clinical trials will take significant time and safety testing. Clinicians must also consider if blocking CXCR6 might inadvertently affect T cell infiltration into the tumor microenvironment, although some studies suggest that the chemokine requirements for tumor infiltration may differ from those of the myocardium.
Conclusion: A Paradigm Shift in Treatment
The study by Munir and colleagues establishes CXCR6+ T cells as the central orchestrators of ICI-induced myocarditis. By demonstrating that the CXCR6-CXCL16 axis is necessary for disease pathogenesis, the research provides a clear biological rationale for developing targeted therapies. As the use of combination therapies like relatlimab and nivolumab becomes more common, the ability to specifically intervene in the cardiotoxic pathway while preserving oncological gains will be the “holy grail” of cardio-oncology. This work moves us one step closer to that goal, offering hope for a more precise and safer approach to managing one of the most serious complications of modern cancer therapy.
References
1. Munir AZ, Gutierrez A, Krawiec CJ, et al. CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. Circulation. 2026;153(10):754-768. PMID: 41498147.
2. Salem JE, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589.
3. Moslehi JJ, et al. Cardiovascular toxicities associated with checkpoint inhibitors: an emerging, cross-disciplinary issue. CA Cancer J Clin. 2018;68(6):453-464.
